Investing.com UK - Financial Markets Worldwide
🎁 💸 Warren Buffett's Top Picks Are Up +49.1%. Copy Them to Your Watchlist – For FreeCopy Portfolio

RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate

Published 19/10/2022, 17:34
© Redhill Biopharma PR RedHill Biopharma Shares Surge New Treatment Patent For Its Late-Stage COVID-19 Candidate
RDHL
-

  • The United States Patent and Trademark Office (USPTO) granted a further method of use patent for RedHill Biopharma Ltd's (NASDAQ: RDHL) COVID-19 treatment, opaganib.
  • The move grants a new method of use patent to inhibit COVID-19 in patients with pneumonia and receiving supplemental oxygen at a fraction of inspired oxygen (FiO2) up to and including 60%.
  • The new patent, expiring in 2041, protects the results from a post-hoc analysis from the global Phase 2/3 study in hospitalized patients with COVID-19 pneumonia.
  • Related: RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5.
  • In the analysis of 251 participants requiring a FiO2 up to and including 60% at baseline (54% of study participants), oral opaganib resulted in a 62% reduction in mortality, improved outcomes in time to room air and median time to hospital discharge, and a reduced likelihood of intubation and mechanical ventilation.
  • Late-stage development of opaganib is ongoing pending Phase 3 trial design regulatory approvals and securing of external funding.
  • Price Action: RDHL shares are up 50.90% at $0.70 on the last check Wednesday.
© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Read the original article on Benzinga

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.